USOR - Comprehensive Cancer Centers of Nevada - Central Valley — Las Vegas, Nevada

USOR - Comprehensive Cancer Centers of Nevada - Central Valley is a clinical research site located in Las Vegas, Nevada, United States 89119.

Crixeo Clinical Trials Trust Score: 4/100 (FAILING). This profile has not yet been claimed by the site owner.

USOR - Comprehensive Cancer Centers of Nevada - Central Valley has participated in 1 clinical trials.

Therapeutic areas: Multiple Myeloma.

Sponsors: Teva Branded Pharmaceutical Products R&D LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Las Vegas

Browse all research sites in Nevada · View every site in Las Vegas

Sponsor Feasibility Report

Trust Score: 4/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for USOR - Comprehensive Cancer Centers of Nevada - Central Valley?

USOR - Comprehensive Cancer Centers of Nevada - Central Valley has a Crixeo Trust Score of 4/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has USOR - Comprehensive Cancer Centers of Nevada - Central Valley conducted?

USOR - Comprehensive Cancer Centers of Nevada - Central Valley has 1 clinical trials on record. Their work covers Multiple Myeloma.

Is USOR - Comprehensive Cancer Centers of Nevada - Central Valley accredited by Crixeo Clinical Trials?

USOR - Comprehensive Cancer Centers of Nevada - Central Valley has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about USOR - Comprehensive Cancer Centers of Nevada - Central Valley?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.